Search company, investor...

BioValve

biovalve.com

Founded Year

1998

Stage

Unattributed VC - III | Alive

Total Raised

$12.5M

Last Raised

$8.5M | 20 yrs ago

About BioValve

BioValve offers drug delivery systems

Headquarters Location

9 Campus Drive 2nd Floor East

Parsippany, New Jersey, 07054,

United States

508-845-1177

Missing: BioValve's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: BioValve's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest BioValve News

Safety and Performance Outcomes Published for Biotronik’s Biovalve TAVR Device

Oct 18, 2019

Safety and Performance Outcomes Published for Biotronik’s Biovalve TAVR Device   October 18, 2019—In Journal of the American College of Cardiology (JACC): Cardiovascular Interventions , Ulrich Schäfer, MD, et al published findings from the first-in-human BIOVALVE I and II studies of the safety and performance of the newly introduced Biovalve transfemoral self-expanding supra-annular transcatheter heart valve (Biotronik). BIOVALVE-I is a prospective, single-center feasibility study enrolling 13 high-risk patients with severe aortic stenosis, and BIOVALVE-II is a multicenter pilot study enrolling a further 55 patients under the same protocol. Patients’ mean age was 82.4 ± 5.3 years, 57.4% had concomitant coronary artery disease, 50% had renal insufficiency stage ≥ 3, 32.4% had diabetes mellitus, 29.4% had current anemia, 19.1% had chronic obstructive pulmonary disease, 19.1% were frail, and 17.6% had prior cerebrovascular events. As summarized in JACC: Cardiovascular Interventions, the primary endpoint—early safety according to the Valve Academic Research Consortium-2 guidelines—was observed in 13 (19.1%) patients. The investigators found the following at 30 and 180 days, respectively: Noncardiac death in one (1.5%) and four (7.8%) patients Disabling stroke in one (1.5%) and two (3.2%) patients Moderate or severe paravalvular leakage in two (3.8%) and four (9.1%) patients Mean effective orifice area was 2.0 ± 0.4 and 1.9 ± 0.5 cm2 The mean gradient was 6.4 mm Hg at both intervals Additionally, new permanent pacemakers were implanted in nine (13.4%) patients at 30 days. The clinical outcomes with the Biovalve self-expanding transcatheter heart valve were similar to those seen in other first-in-human studies with first-generation devices for severe aortic stenosis, concluded the investigators in JACC: Cardiovascular Interventions. advertisement

BioValve Frequently Asked Questions (FAQ)

  • When was BioValve founded?

    BioValve was founded in 1998.

  • Where is BioValve's headquarters?

    BioValve's headquarters is located at 9 Campus Drive, Parsippany.

  • What is BioValve's latest funding round?

    BioValve's latest funding round is Unattributed VC - III.

  • How much did BioValve raise?

    BioValve raised a total of $12.5M.

  • Who are the investors of BioValve?

    Investors of BioValve include BioVentures Investors, MPM Capital, Seaflower Ventures and Earlybird Venture Capital.

  • Who are BioValve's competitors?

    Competitors of BioValve include PharmaJet, Hutchison MediPharma, Valeritas, Pantec Biosolutions, Replenish and 11 more.

Compare BioValve to Competitors

U
UMD

UMD aims to develop drug delivery technologies and products, with a focus on women's health.

T
The Liposome Company

The Liposome Company is developing liposome-based drug delivery

C
Cytogel

Cytogel, Inc., is working on the development of promising drug candidates and drug delivery technologies

D
Depotech

Depotech is developing methods for drug delivery

R
Replenish

Replenish Inc is a Pasadena, Calif.-based developer of a drug delivery platform.

M
Medlogics

Medlogics is an early stage medical device company developing a broad platform technology for drug delivery. The initial focus is product development of polymer-free stent drug delivery.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.